Transplant Cell Ther 2021 May 31. Epub 2021 May 31.
Department of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; Leukemia Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Electronic address:
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the most effective post-remission therapy conferring the chance of cure for acute myeloid leukemia (AML), including elderly patients. Although the number of transplants for elderly patients with AML (eAML) is increasing owing to greater availability of various graft sources together with the adoption of advanced supportive care and reduced-intensity conditioning (RIC) regimen, there are relatively limited data on the impact of donor type in eAML compared to younger patients. In addition, few studies have evaluated the role of pre-transplant measurable residual disease (MRD) in elderly population. Read More